Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Abstract Purpose: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment
(TME) play a central role in tumor progression. We investigated whether CAFs can regulate …

BACKGROUND MEK inhibitors have limited activity in biliary tract cancers (BTCs) as
monotherapy but are hypothesized to enhance responses to programmed death ligand 1 …

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …

We are witnessing several revolutionary technological advances in cancer. These
innovations have not only contributed to a growing understanding of the tumor and its …